Ankit Mahadevia
Principal @ Atlas Venture
Cambridge, United States
Ankit Mahadevia is a Series A investor at Atlas Venture in Cambridge focused on Health Care and Therapeutics. Dr. Ankit Mahadevia is an entrepreneur, physician, author, and advisor focused on building and supporting innovative biotechnology companies. He currently serves as a CXO at Curie Bio, where he works closely with leadership teams on company formation, strategy, financing, and advancement toward human clinical trials.In addition to his operatingrole, Dr. Mahadevia serves as an independent board member and advisor to multiple early- and growth-stage life sciences companies. Since 2023, he has been an advisor and board member at Judo Bio, a company developing novel oligonucleotide therapeutics for kidney disease. He also advises Inductive Bio (New York) and Oath Bio (San Francisco). Over the course of his career, companies he has led, advised, or supported have collectively raised more than $1 billion in financing.Dr. Mahadevia is the author of Quiet Leader Loud Results (Post Hill Press, 2022), which explores how introverted leaders can achieve meaningful organizational impact while leading authentically. He has spoken widely on leadership and innovation, including at the Wharton School, Northwestern University, Harvard University, large pharmaceutical companies, nonprofit organizations, and startups.He is a member of Life Science Cares, a nonprofit organization dedicated to reducing poverty and inequality through engagement with the life sciences industry.Dr. Mahadevia graduated summa cum laude from Northwestern University with a degree in economics and biology. He earned his MD from the Johns Hopkins University School of Medicine and his MBA in healthcare management from the Wharton School of the University of Pennsylvania.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Ankit Mahadevia invests in
Stages Ankit Mahadevia invests in
Countries Ankit Mahadevia invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (25%)
- Therapeutics 1 (25%)
- Biotechnology 1 (25%)
Stage
- Series A 1 (25%)
- Series B 1 (25%)
- Series C 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. The company's lead programs target patients with rare genetic metabolic diseases, including phenylketonuria and secondary hyperoxaluria. Synlogic is also hard at work on synthetic biotics to address more prevalentconditions, including inflammatory bowel disease, cancer, and other metabolic conditions. | Series C / May 16, 2017 | ||
| Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. The company's lead programs target patients with rare genetic metabolic diseases, including phenylketonuria and secondary hyperoxaluria. Synlogic is also hard at work on synthetic biotics to address more prevalentconditions, including inflammatory bowel disease, cancer, and other metabolic conditions. | $40M / Series B / Feb 17, 2016 | ||
| Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. The company's lead programs target patients with rare genetic metabolic diseases, including phenylketonuria and secondary hyperoxaluria. Synlogic is also hard at work on synthetic biotics to address more prevalentconditions, including inflammatory bowel disease, cancer, and other metabolic conditions. | Series A / Oct 07, 2014 | ||
| Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. The company's lead programs target patients with rare genetic metabolic diseases, including phenylketonuria and secondary hyperoxaluria. Synlogic is also hard at work on synthetic biotics to address more prevalentconditions, including inflammatory bowel disease, cancer, and other metabolic conditions. | $29.4M / Series A / Jul 22, 2014 |
Co-Investors
About Atlas Venture
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Atlas Venture Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Chelsea Place Johnson
Principal
|
|||
Ed Holson
Entrepreneur-in-Residence
|
|||
Jean-Francois Formela
Partner
|
|||
Kevin Bitterman
Partner
|
|||
Michael Gladstone
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ankit Mahadevia invest in?
Ankit Mahadevia invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ankit Mahadevia?
Public channels for Ankit Mahadevia include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ankit Mahadevia last invest?
The most recent investment recorded for Ankit Mahadevia closed in May 2017. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
